Back to results
US 12,767,990 B2Granted
EPLIN as a biomarker for cancer
AssigneeThestra Oy
InventorsSami Ventelä, Jukka Westermarck
Life of this patent
Estimating the term…
Abstract
The present invention relates to EPLIN as a biomarker for cancer and particularly small-size (T1/T2N0 and/or stage I/II) cancer. Thus, the invention provides use of EPLIN and an in vitro method of prognosing cancer or diagnosing aggressive cancer in a subject on the basis of the expression level of EPLIN. Also provided is a method for selecting treatment for cancer or predicting response to treatment. Also provided is a kit for use in said methods.
Claims9
A method of treating HNSCC cancer in a subject, the method comprising:
- a) assaying a HNSCC sample obtained from said subject for expression level of EPLIN,
- b) selecting as a treatment either:
- (i) monotherapy with surgery when the expression of EPLIN is non-increased or decreased as compared to a relevant control level;
- or
- (ii) chemotherapy in combination with dissection, radiotherapy, or both dissection and radiotherapy, when the expression of EPLIN is increased as compared to the relevant control level;
- and
- c) administering the selected treatment to the subject.
4 more elements
Dependencies are inferred from the claim text.